ClinicalTrials.gg
RecruitingNCT06164444DRAGONUpdated Nov 16, 2026

Disposable Versus Reusable drApes and Gowns for Green OperatiNg Theatres

An interventional study of Intervention: Reusable drapes and gowns and Comparator: Disposable (single-use) drapes and gowns in Surgical Site Infection, sponsored by University of Birmingham. Recruiting at 7 sites in 7 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Birmingham · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 16, 2026First sites in 6 new countriesSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26,800
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Study summary

Multicentre non-inferiority cluster randomised trial testing Disposable versus Reusable drApes and Gowns for green OperatiNg theatres. A pragmatic 1:1 international multi-centre non-inferiority cluster randomised controlled trial, with an internal pilot. Clusters are individual hospitals.

Read the detailed description

Background: The World Health Organisation makes no recommendation for the use of disposable or reusable surgical drapes and gowns due to a lack of effectiveness evidence. Since disposable versions are likely to have higher financial and carbon costs, they are only justifiable if they can be proven to significantly reduce surgical site infections (SSIs).

Aim: This randomised controlled trial will assess whether reusable surgical drapes and gowns are non-inferior in reducing SSI compared to disposable drapes and gowns in patients undergoing surgery.

Design: Pragmatic 1:1 international multi-centre non-inferiority cluster randomised controlled trial, with an internal pilot. Clusters are individual hospitals.

Intervention: Reusable surgical drapes and gowns.

Comparator: Disposable (single-use) surgical drapes and gowns.

Sample size: The control group SSI event rate is estimated to be 12.5% based on previous literature. To determine whether reusable drapes and gowns are non-inferior to disposable drapes and gowns with a non-inferiority margin of 2.5% would require a total of 26,800 participants from 134 clusters, with an average of 200 participants per cluster, assuming 90% power, 2.5% one-sided alpha, intraclass correlation of 0.01 and 5% participant loss to follow up.

02

Conditions studied

  • Surgical Site Infection

Keywords

  • Surgery
  • global surgery
  • SSI
  • surgical site infection
03

In context

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

This study's planned enrollment of 26,800 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

University of Birmingham is the lead sponsor of 182 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with at least one incision that is ≥5cm in adults and ≥3cm in children aged under 16 years. This can include both open and minimally-invasive surgery providing at least one incision meets this criteria.
  • Patients with a clean-contaminated, contaminated, or dirty surgical wound. Definitions of contamination are given in Table 2.
  • Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) surgery.
  • Any operative indication (including caesarean section).
  • Patients aged 10 or over.

Exclusion criteria

Exclusion criteria

  • Adults with an incision \<5 cm and incision \<3cm in children aged under 16 years.
  • Patients undergoing procedures with a clean surgical wound only.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
26,800 participants (estimated)

Study arms

  • Experimental
    Intervention: Reusable drapes and gowns

    * Reusable drapes and gowns are made from cotton and polyester and are protective against fluid contamination and, to a certain extent, mechanical stress. * Reusable drapes and gowns are usually autoclaved and laundered using pressurised steam. This ensures that bacteria and other microorganisms are killed, sterilising the fabric so it is suitable for re-use. In this pragmatic trial, a specific sterilisation protocol is not mandated, but details of the sterilisation processes in place at each hospital will be captured in the Hospital-level Questionnaire before site opening. We may report this in a paper ahead of the main trial publication.

    Other: Intervention: Reusable drapes and gowns

  • Active comparator
    Comparator: Disposable (single-use) drapes and gowns

    * Single-use surgical gowns and drapes are generally made from non-woven plastic polymers that are protective against fluid contamination and, to a certain extent, mechanical stress. * They are intended for use during a single operation and are then disposed of as biohazard waste for incineration. * Typically, four drapes are needed for an abdominal operation (two larger and two smaller drapes), although more may be needed for some procedures. * A range of disposable gowns are available. The choice of disposable gown will be at the hospital PI's discretion and will be captured in the Hospital-level Questionnaire.

    Other: Comparator: Disposable (single-use) drapes and gowns

Interventions

  • OtherIntervention: Reusable drapes and gowns

    Reusable drapes and gowns used during surgery.

  • OtherComparator: Disposable (single-use) drapes and gowns

    Disposable drapes and gowns used during surgery.

06

What researchers measure

Primary outcomes

  1. Surgical site infection (SSI)

    SSI according to centre for disease control (CDC) criteria: The infection must occur within 30-days of the index operation AND The infection must involve the skin, subcutaneous, muscular, or fascial layers of the incision AND The patient must have at least one of the following: Purulent drainage from the wound Organisms are detected from a wound swab Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of pain or tenderness; localised swelling; redness; heat; systemic fever (\>38°C). Diagnosis of SSI by a clinician or on imaging

    Time frame: Within 30 days of surgery

Secondary outcomes

  1. Mortality (and likely cause)

    Time frame: Within 30 days of surgery

  2. Unplanned wound opening

    Time frame: Within 30 days of surgery

  3. Antibiotic prescribing for SSI

    Time frame: Within 30 days of surgery

  4. Reattendance at emergency department

    Time frame: Within 30 days of surgery

  5. Readmission to hospital

    Time frame: Within 30 days of surgery

  6. Reoperation for SSI

    Time frame: Within 30 days of surgery

  7. Total length of hospital stay

    Time frame: Within 30 days of surgery

07

Study locations

4 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Hospital-level data will not be released or published. Country-level analyses will only be conducted with permission of lead investigators from each participating country. Local investigators may access their data across their country to perform country-level analyses (all participating hospitals should consent to their data being used in this way).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

Of 202 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 31 months is above that.

Counting every sponsor, half of 209 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2026 → Jun 2027 and completion Jul 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 11, 2023
StartActual
Nov 12, 2024
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Jul 31, 2027was Jul 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first sites in Benin, Ghana, India, Nigeria, Rwanda and 1 more
All 6 countries

Benin, Ghana, India, Nigeria, Rwanda, South Africa

. CMNO is now Completed
Show 6 added (1 Benin, 1 Ghana, 1 India, 1 Nigeria, 1 Rwanda, 1 South Africa)
  • University of Abomey Calavi · Cotonou, Benin
  • Tamale Teaching Hospital, Tamale · Tamale, Ghana
  • Christian Medical College and Hospital Ludhiana · Ludhiana, India
  • Lagos University Teaching Hospital (Hub), Lagos · Lagos, Nigeria
  • University Teaching Hospital of Kigali (Hub) · Kigali, Rwanda
  • University of the Witwatersrand · Johannesburg, South Africa
Nov 16, 2026
Primary completion
Jun 30, 2026→Jun 30, 2027
Nov 16, 2026
Study completion
Jul 31, 2026→Jul 31, 2027
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • CMNO · Guadalajara, MexicoContact removed d•••@heveracruz.mx · •••4877Contact removed (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    6 sites added — first sites in Benin, Ghana, India, Nigeria, Rwanda and 1 more
    All 6 countries

    Benin, Ghana, India, Nigeria, Rwanda, South Africa

    . CMNO is now Completed
    Show 6 added (1 Benin, 1 Ghana, 1 India, 1 Nigeria, 1 Rwanda, 1 South Africa)
    • University of Abomey Calavi · Cotonou, Benin
    • Tamale Teaching Hospital, Tamale · Tamale, Ghana
    • Christian Medical College and Hospital Ludhiana · Ludhiana, India
    • Lagos University Teaching Hospital (Hub), Lagos · Lagos, Nigeria
    • University Teaching Hospital of Kigali (Hub) · Kigali, Rwanda
    • University of the Witwatersrand · Johannesburg, South Africa
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Jul 31, 2026→Jul 31, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • CMNO · Guadalajara, MexicoContact removed d•••@heveracruz.mx · •••4877Contact removed (no phone or email listed)
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06164444
Collaborators
Christian Medical College, Vellore, India, Kigali University Teaching Hospital, Lagos State University, Hospital Español de Mexico, Christian Medical College and Hospital, Ludhiana, India, Centre National Hospitalier Universitaire Hubert Koutoukou MAGA, University for Development Studies, Tamale, Ghana, Chris Hani Baragwanath Academic Hospital
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Nov 12, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Rachel Lillywhite
Contact
r.e.lillywhite@bham.ac.uk
07739743528
Divya Kapoor
Contact
d.kapoor@bham.ac.uk
+44 (0)121 415 9103
Aneel Bhangu
principal investigator · University of Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion